Additional Proxy Soliciting Materials (definitive) (defa14a)
03 Enero 2019 - 6:47AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
_________________
Date of Report (Date of earliest event reported):
January 3, 2019
Alliqua
BioMedical, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware
|
|
001-36278
|
|
58-2349413
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
2150 Cabot Blvd., West
Suite B
Langhorne, PA
|
|
19047
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (215) 702-8550
Former name or former address, if changed since last report)
|
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
x
|
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications
pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events.
On January 3, 2019, Alliqua BioMedical, Inc. (the “
Company
”)
issued a letter to its shareholders from David I. Johnson, its Chief Executive Officer, describing certain business updates. A
copy of the letter is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Additional Information about the Adynxx Merger and Where to Find It
In connection with the Agreement and Plan of Merger and Reorganization
(the “
Merger Agreement
”), pursuant to which, among other things, subject to the satisfaction or waiver of the
conditions set forth in the Merger Agreement, Embark Merger Sub Inc. will merge with and into Adynxx. Inc. (“
Adynxx
”),
with Adynxx becoming a wholly-owned subsidiary of the Company and the surviving corporation of the merger (the “
Merger
”),
the Company intends to file relevant materials with the SEC, including a definitive proxy statement for its stockholders containing
the information with respect to the Merger and the Merger Agreement specified in Schedule 14A promulgated under the Securities
Exchange Act of 1934, as amended, and describing the proposed Merger. The preliminary proxy statement and other relevant materials
(when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the
SEC’s website at www.sec.gov. In addition, investors and security holders may obtain free copies of the documents filed with
the SEC by the Company by directing a written request to: Alliqua BioMedical, Inc., 2150 Cabot Boulevard West, Suite B, Langhorne,
Pennsylvania 19047. Investors and security holders are urged to read the proxy statement and the other relevant materials when
they become available before making any voting or investment decision with respect to the Merger.
Participants in Solicitation
The Company and its directors and executive officers and Adynxx
and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders
of the Company in connection with the proposed transaction. Information regarding the special interests of these directors and
executive officers in the Merger will be included in the proxy statement referred to above. Additional information regarding the
directors and executive officers of the Company is also included in the Company’s Annual Report on Form 10-K for the year
ended December 31, 2017 and the proxy statement for the Company’s 2018 Annual Meeting of Stockholders. These documents are
available free of charge at the SEC’s website at www.sec.gov and from the Company at the address described above.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements for the
purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities
laws. The use of words such as “may,” “might,” “will,” “expect,” “plan,”
“anticipate,” “believe,” “intend,” “future,” or “continue” and other
similar expressions are intended to identify forward-looking statements. Such statements include, but are not limited to, statements
regarding the structure, timing and completion of our proposed merger with Adynxx; statements regarding the structure, timing and
completion of our proposed merger with TO Pharmaceuticals; our expectations regarding the capitalization, resources and ownership
structure of the Alliqua and TO Pharma following the transactions; our expectations regarding our and TO Pharma’s ability
to trade on the Nasdaq Capital Market; the executive officer and board structure of the each organization; and the expectations
regarding voting by Alliqua and Adynxx stockholders. Alliqua, AquaMed, TO Pharmaceuticals and/or Adynxx may not actually achieve
the proposed mergers, or any plans or product development goals in a timely manner, if at all, or otherwise carry out the intentions
or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on
these forward-looking statements. These statements are also subject to a number of material risks and uncertainties that are described
in Alliqua BioMedical, Inc.’s preliminary proxy statement, filed with the Securities and Exchange Commission on November
26, 2018. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly
update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required
by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ALLIQUA BIOMEDICAL, INC.
|
|
|
|
|
|
|
Dated: January 3, 2019
|
By:
|
/s/ Joseph Warusz
|
|
|
Name: Joseph Warusz
|
|
|
Title: Chief Financial Officer
|
Alliqua, Inc. (NASDAQ:ALQA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Alliqua, Inc. (NASDAQ:ALQA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024